Inc that they have come to a preliminary determination
that the drugmaker's experimental stomach ulcer drug did not
show bioequivalence with 325 mg aspirin, further jeopardizing
the drug's chances to win approval soon.
Wednesday, June 20, 2012
UPDATE 1-FDA says Pozen ulcer drug may need more data, shares plunge
June 20 (Reuters) - U.S. health regulators informed Pozen
Inc that they have come to a preliminary determination
that the drugmaker's experimental stomach ulcer drug did not
show bioequivalence with 325 mg aspirin, further jeopardizing
the drug's chances to win approval soon. 
Inc that they have come to a preliminary determination
that the drugmaker's experimental stomach ulcer drug did not
show bioequivalence with 325 mg aspirin, further jeopardizing
the drug's chances to win approval soon.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment